Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125716121 | 12571612 | 1 | I | 20160624 | 20160707 | 20160719 | 20160719 | EXP | UA-BAYER-2016-132931 | BAYER | 57.00 | YR | A | M | Y | 0.00000 | 20160719 | CN | UA | UA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125716121 | 12571612 | 1 | PS | NEXAVAR | SORAFENIB | 1 | 400 MG, QD | 7600 | MG | 21923 | 400 | MG | FILM-COATED TABLET | QD | |||||
| 125716121 | 12571612 | 2 | C | SIBAZON | 2 | 0 | |||||||||||||
| 125716121 | 12571612 | 3 | C | MAGNESIUM | MAGNESIUM | 1 | 0 | ||||||||||||
| 125716121 | 12571612 | 4 | C | CEREBROLYCIN | 2 | 0 | |||||||||||||
| 125716121 | 12571612 | 5 | C | CEFTRIAXON | CEFTRIAXONE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125716121 | 12571612 | 1 | Hepatocellular carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125716121 | 12571612 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125716121 | 12571612 | Hypertension | |
| 125716121 | 12571612 | Ischaemic stroke |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125716121 | 12571612 | 1 | 20160606 | 20160624 | 0 |